Vectura News

Discover more about our company, science, innovation and people with the latest headlines from Vectura.

Displaying 43 of 43

Vectura provides update on GSK litigation

Vectura Group plc (LSE: VEC) (“Vectura”), an industry-leading inhalation CDMO, announces that the United States Court of Appeals for the...

Published19/11/2020

Read more
Will Downie’s podcast: “There’s a patient at the end of every piece of work we do…”

In the latest podcast in our series,  Will Downie, Vectura’s CEO, talks about coping with the COVID crisis, our CDMO...

Published08/10/2020

Read more
Vectura shortlisted for ’Excellence in Pharma: Contract Services and Outsourcing’

We are delighted to announce that we have been shortlisted for the category ’Excellence in Pharma: Contract Services and Outsourcing’,...

Published24/09/2020

Read more
Status update on VR315 (US)

Vectura Group confirms the announcement made today by its partner Hikma Pharmaceuticals.  Hikma has received a minor complete response letter...

Published22/09/2020

Read more
2020 Interim Results

Vectura reports 2020 financial performance on-track Company demonstrates progress on strategy execution with 12 new CDMO deals signed year to...

Published15/09/2020

Read more
Vectura partners with Monash University to support development of inhaled oxytocin to prevent postpartum haemorrhage

Vectura announces that it has signed an agreement with Monash University’s Institute of Pharmaceutical Sciences (MIPS), to develop inhaled oxytocin...

Published14/09/2020

Read more
Notice of Interim Results

Vectura Group plc plans to announce its Interim Results for the six-months ended 30 June 2020 on Tuesday 15 September...

Published06/08/2020

Read more
QVM149 receives regulatory approval in Europe and Japan

Vectura today confirms the announcement made by Novartis that the European Commission has approved QVM149;indacaterol acetate, glycopyrronium bromide and mometasone...

Published07/07/2020

Read more
Live Webcast 24th June: Dry Powder Inhalers – Key Considerations for Combination Product Development

Andreas Meliniotis, Director of Device Development at Vectura, discusses the key considerations to reduce risk when developing a DPI product...

Published17/06/2020

Read more
Vectura signs agreement with Aerami Therapeutics Inc.

Today we announce the signing of a global licence and development agreement with Aerami Therapeutics Inc. for inhaled imatinib (VR325)...

Published08/06/2020

Read more
Vectura expands business development team with three global appointments

Vectura today announced three appointments to its business development team, as it continues its strategy to become a leading inhalation...

Published03/06/2020

Read more
Podcast: Breathing new life into existing drugs

Repurposing or repositioning a drug is often a faster and more affordable way to develop new products than de novo...

Published28/05/2020

Read more
Share buyback and AGM trading update

Today we publish a trading update, ahead of our Annual General Meeting (AGM). The Board maintains its financial guidance and...

Published27/05/2020

Read more
Podcast: Vectura presents latest science at Digital RDD 2020

Vectura is presenting some of its most recent science in five poster presentations at the virtual Respiratory Drug Delivery (RDD)...

Published17/04/2020

Read more
Vectura’s response to the COVID-19 outbreak

Events in relation to the COVID-19 outbreak continue to evolve rapidly, and the Group is monitoring the situation closely as...

Published19/03/2020

Read more
Vectura publishes 2019 preliminary results

Vectura Group plc today announces its preliminary results for the year ended 31 December 2019. For full details, please click...

Published17/03/2020

Read more
Vectura appoints Mark Bridgewater as Chief Commercial Officer

Vectura Group plc today announced a key leadership appointment to drive business development and growth as the Company continues with...

Published09/03/2020

Read more
Sharon Johnson appointed Executive Vice President for Delivery Management

Vectura Group plc today announces a key appointment to support innovation, customer focus and growth as the company continues with...

Published10/02/2020

Read more
Pre-close trading update confirms 2019 trading in-line with expectations

Vectura Group plc today announces an unaudited 2019 pre-close trading update. The Group expects revenue and Adjusted EBITDA to be...

Published13/01/2020

Read more
Meet our inhalation experts at Drug Delivery to the Lungs (DDL) 2019

Are you looking to develop an inhaled product? Do you need an experienced partner with specialist inhalation expertise to support...

Published03/12/2019

Read more
VR315US: Hikma submits response to FDA

Vectura Group notes today’s announcement by Hikma Pharmaceuticals, its partner in the development of an AB rated substitutable US generic...

Published27/11/2019

Read more
Vectura to present latest science at Drug Delivery to the Lungs (DDL) 2019

Vectura Group plc, a leading inhalation focused CDMO business, will present some of its most recent science in six poster...

Published22/10/2019

Read more
Vectura Group appoints New Chief Executive Officer

Vectura Group plc is pleased to announce the appointment of Will Downie as CEO and Executive Director of the Company...

Published15/10/2019

Read more
Results of the General Meeting held on 10th October 2019

All resolutions proposed to shareholders at a General Meeting held this morning were duly passed on a poll. The meeting...

Published10/10/2019

Read more
Board change

Vectura Group announces that Dr Susan Foden is stepping down from the Board and her role as Senior Independent Non-Executive...

Published26/09/2019

Read more
Vectura provides update on GSK litigation

Today Vectura announces that following the award of US$89.7m in damages to Vectura by a jury in the US District...

Published13/09/2019

Read more
Vectura delivers strong H1 2019 financial performance

Vectura Group today announces its unaudited Interim Results for the six months ended 30 June 2019. For the full RNS...

Published10/09/2019

Read more
Proposed increased capital return to shareholders of approx. £60m

Vectura Group plc: Proposed Special Dividend and Share Consolidation, Share Buyback Programme and Dividend Reinvestment Plan On 17 July 2019,...

Published09/09/2019

Read more
Proposed £50 million capital return and trading update

Vectura Group plc today confirms its R&D investment priorities, announces a proposed £50 million capital return and provides an unaudited...

Published17/07/2019

Read more
Vectura Group Plc announces leadership changes

Vectura Group today announces that James Ward-Lilley will be stepping down from the Board and his position as Chief Executive...

Published10/06/2019

Read more
QVM149 submission means early $2.5m payment for Vectura

Vectura announced today that it will receive a $2.5million milestone payment under an exclusive licence agreement with Novartis AG. The...

Published24/05/2019

Read more
Vectura data to be shared at ATS 2019

Vectura is sharing new data at the ATS International Conference 2019 in Dallas, US. We’re proud of our research and...

Published15/05/2019

Read more
Vectura wins US GSK patent litigation and awarded $89.7m in damages by jury

Vectura Group confirms that on 3rd May 2019, following a jury trial in the United States District Court for the...

Published26/04/2019

Read more
R&D: Transformation frees up more resources for innovation

Our recently transformed R&D ways of working have freed up time and resources for new, innovative programmes so we can...

Published10/04/2019

Read more
Vectura reports strong 2018 financial and operational performance

Vectura Group plc today announces its preliminary results for the year ended 31 December 2018. For full details, please click here....

Published26/03/2019

Read more
Pre-close trading update confirms good progress against 2018 goals

Vectura Group plc today announces an unaudited 2018 pre-close trading update. The Group expects revenue to be in line with,...

Published03/01/2019

Read more
Global agreement with Hikma to develop generic versions of GSK’s Ellipta® portfolio

Vectura Group today announces signing an agreement with Hikma Pharmaceuticals for the global development and commercialisation of generic versions of...

Published08/11/2018

Read more
Rising to the challenge of developing inhaled generic medicines

Developing generic medicines helps provide affordable alternatives to branded products, ultimately providing patients with lower cost access to expensive treatments....

Published26/09/2018

Read more
Vectura Group Interim Results for H1 2018

Chippenham, UK – 11 September 2018: Vectura Group plc (LSE: VEC) (“Vectura” or “the Group”) announces its unaudited Interim Results...

Published11/09/2018

Read more
Fundraising for AsthmaUK

An intrepid group of cyclists from Vectura Group challenged themselves to cover 450 Kilometres (280 miles) over 3.5 days as...

Published06/07/2018

Read more
Bringing nebuliser device and formulation together

Sandy Munro, VP Pharmaceutical Development, introduces Vectura’s Science Live campaign, the work of his nebuliser product development team and the...

Published05/07/2018

Read more
New product creation – from paper to market

When the Vectura team of engineers set out to design a new respiratory device they follow a tried and tested...

Published04/07/2018

Read more
Generic programmes

A generic drug is a medication that has exactly the same active ingredient as its equivalent brand-name drug and yields...

Published03/07/2018

Read more

Displaying 43 of 43